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Abstract
Background: The CC chemokine receptor 9 (CCR9) plays an important role in tumorigenesis and metastasis in
various cancers. Our previous studies have shown the aberrant expression of CCR9 in non-small cell lung cancer
(NSCLC) cell lines, revealing that the CCR9-CCL25 axis modulates cell migration and invasion, and supports cancer
cell survival by inhibiting apoptosis in vitro and in vivo. In the present study, we aimed to evaluate the expression
and possible prognostic role of CCR9 in lung adenocarcinoma.
Methods: Immunohistochemical analysis of CCR9 expression was performed on 144 lung adenocarcinoma tissues
and 30 adjacent normal lung parenchymal tissues. We assessed the correlation of CCR9 expression with
clinicopathological characteristics and the prognosis of lung adenocarcinoma.
Results: The expression of CCR9 was increased in lung adenocarcinoma tissue compared with normal lung tissue.
Moreover, such an expression was positively correlated with tumor size (p = 0.032), lymph node metastasis (p =
0.002) and advanced TNM stage (p = 0.012). In addition, the patients with negative CCR9 expression exhibited a
higher overall survival (OS) compared with those with positive CCR9 expression. Multivariate analysis showed that
the CCR9 expression was an independent prognostic factor for the OS of patients with lung adenocarcinoma.
Conclusions: We, for the first time, reported that CCR9 could be beneficial in predicting lymph node metastasis,
and it might act as a novel prognostic biomarker for lung adenocarcinoma.
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Background
Lung cancer is the leading cause of malignancy-related
deaths for both men and women worldwide [1]. Non-
small cell lung cancer (NSCLC) is the predominant
component of lung cancer cases. As the most frequent
subtype, lung adenocarcinoma accounts for approximately
40 % of all NSCLC cases, and it has a poorer prognosis
relative to lung squamous cell cancer. Despite the great
progress has been made in the diagnosis and surgical
treatment of lung cancer in recent decades, the overall
tumor-free 5-year survival rate for human lung adenocar-
cinoma remains exceedingly low (below 18 %) due to
metastatic relapse [2]. Nevertheless, the molecular mecha-
nisms and factors involving in the process of adenocarcin-
oma pathogenesis and metastasis are not fully elucidated.
Therefore, it is necessary to identify novel molecular bio-
markers, which may help in providing new therapeutic
targets and improving the survival of patients with lung
adenocarcinoma.
As members of a superfamily of small inflammatory or
homeostatic cytokines, chemokines share a common bio-
logical activity in stimulating the migration of different
types of cells, including lymphocytes, monocytes, neutro-
phils, endothelial cells and mesenchymal stem cells
[3]. Biologically, in addition to leukocyte recruitment,
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chemokine receptors and its corresponding ligands are as-
sociated with tumor progression, angiogenesis and metas-
tasis [4, 5]. In recent years, chemokine receptors have
been recognized as new potential targets or agents in can-
cer therapy and immunotherapy, suggesting their multifa-
ceted role in the development and progression of cancer
[6].
CC chemokine receptor 9 (CCR9) is a G-protein-
coupled receptor for the thymus-expressed chemokine
(TECK) or CCL25, and the latter one is the only natural
ligand of CCR9 [7]. CCR9 is preferentially expressed on
subsets of naive T cells and mature dendritic cells, and it
was initially identified for its role in immune homeosta-
sis, which is responsible for recruiting immune cells [8].
Notably, many different reports have shown that CCR9
is highly expressed in various cancer cells and tumors,
functioning as a critical potential mediator in cancer
progression [9]. Furthermore, in our previous study, for
the first time, we have shown the potential role of CCR9
in lung cancer, demonstrating that it is significantly
over-expressed in tissues and cell lines from NSCLC,
and CCR9-CCL25 axis promotes the migration and inva-
sion capability of NSCLC cells in vitro [10]. Our subse-
quent study suggested that CCR9-CCL25 interaction
supports lung cancer cell survival and up-regulates the
anti-apoptotic signaling mediated by the PI3K/Akt sur-
vival pathway [11].
Therefore, we focus on the clinical significance of the
CCR9-CCL25 biological axis, which appears to be associ-
ated with both good and bad outcomes in cancer progno-
sis. No studies have examined the expression profiles of
CCR9 in lung adenocarcinoma patients with curative re-
section and its effect on lung adenocarcinoma survival. In
the present study, we aimed to investigate the expression
of CCR9 in lung adenocarcinoma tissue and its correla-
tions with clinicopathological characteristics. Moreover,
we attempted to evaluate the relationship between CCR9
expression and post-operative prognosis.
Methods
Patients and tissue samples
Formalin-fixed, paraffin-embedded specimens of 144 lung
adenocarcinoma tissue were collected from the People's
Hospital of Guangxi Zhuang Autonomous Region (Nan-
ning, P. R. China) between 2008 and 2012. Paired normal
lung parenchyma specimens were collected from adjacent
tissues (> 5 cm away from tumors) of 30 randomly se-
lected cases. The median age of these 144 patients with
lung adenocarcinoma, including 95 males and 49 females,
was 58 years old ranging from 32 to 78. All the patients
underwent complete pulmonary lobectomy or segment re-
section and simultaneously received hilar and/or medias-
tinal lymph node dissections. Pathological staging was
performed for all cases according to the revised 7th Edition
of the Union for International Cancer Control (UICC).
There were 57 cases in stage I, 31 cases in stage II and 56
cases in stage III. Pathological diagnosis was confirmed by
two independent pathologists in the Department of Path-
ology of the People’s Hospital of Guangxi Zhuang Au-
tonomous Region according to 2009 WHO/IASLC. None
of the patients received radiotherapy or chemotherapy be-
fore surgical resection. A total of 73 patients were treated
with routine adjuvant platinum-based chemotherapy after
surgery. Our study protocol was approved by the Ethics
Committees/Institutional Review Boards of the People’s
Hospital of Guangxi Zhuang Autonomous Region, and
written informed consent was obtained from every
participant.
Immunohistochemistry
Envision method was employed to detect the immunohis-
tochemical expression of CCR9 on formalin-fixed, paraffin-
embedded tissue sections. Briefly, the sections were baked
at 65 °C for 60 min, then successively deparaffinized, dehy-
drated and rinsed with phosphate-buffered saline (PBS).
Subsequently, sections were processed in citrate buffer
(0.01 M, pH 6.0) and treated with high-pressure antigen re-
trieval, followed by treatment with 0.3 % hydrogen peroxid-
ase for 10 min to quench the endogenous peroxidase
activity. After the sections were washed with PBS, they were
incubated with rabbit anti-CCR9 polyclonal antibody
(1:100; Abcam, Cambridge, MA, USA) overnight at 4 °C.
Then the slides were respectively incubated with polymer
helper (PV9000 kits, Zhongshan Bio Corp., Beijing, China)
and poly peroxidase-anti-mouse/rabbit IgG antibody
(PV9000 kits, Zhongshan Bio Corp., Beijing, China) at
room temperature for 30 min. After the incubation, the
sections were washed with PBS and developed with diami-
nobenzidine (DAB) (Zhongshan Bio Corp., Beijing, China)
at room temperature for 5 min. Finally, the sections were
counterstained with hematoxylin (Sigma, MO, USA), dehy-
drated and then mounted. For negative controls, the pri-
mary antibody was replaced by PBS. The sections with
positive CCR9 expression severed as positive controls, and
only cytoplasmic staining was considered positive.
Evaluation of immunohistochemical staining
The immunostained slides were independently assessed
by two experienced pathologists blinded to the clinico-
pathologic information. Briefly, representative areas of
each section were selected, and cells were counted in
five fields at a 400-fold magnification. Scores for the tumor
cells stained positive were defined as follows: 0, ≤ 5 %; 1, >
5 to 25 %; 2, > 25 to 50 %; and 3, > 50 %. Staining intensity
was graded according to the following criteria: 0, no
staining; 1, weak staining; 2, moderate staining; and 3,
strong staining. Based on the semi-quantitative score
calculated by multiplying these two values (which ranged
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from 0–9), the stained sections were defined as either nega-
tive expression (0) or positive expression (1–9).
Follow-up
Follow-up visits were postoperatively scheduled at inter-
vals of 1 month, 6 months, first year, 2 years and annually
after surgery, respectively. Follow-up data were mainly ob-
tained through special outpatient reexamination, letters or
telephones. Over survival (OS) was defined as the interval
between the date of surgery and the date of the death or
the date of last visit (if death did not occur). Complete
follow-up, ranging from 1 to 86 months, was available for
all patients, and the median survival was 32 months.
Statistical analysis
Associations between CCR9 expression and clinicopath-
ological parameters were assessed using the χ2 test as
well as the Fisher's exact test. Kaplan-Meier method
with the log-rank test was applied for survival analysis.
Multivariate analysis of the variable influence on OS was
performed using the Cox-proportional hazards model.
All statistical analyses were performed using the SPSS
18.0 software package (SPSS Inc., Chicago, IL, USA). All
p-values were two-sided, and p < 0.05 was considered as
statistically significant.
Results
CCR9 is highly expressed in lung adenocarcinoma
CCR9 expression at the protein level was examined by im-
munohistochemistry on 144 lung adenocarcinoma tissues
and 30 adjacent normal lung tissues (used as normal con-
trols). Figure 1 shows that no CCR9 expression or very
weak staining was observed in normal lung epithelia. In
contrast, the CCR9 expression was predominantly de-
tected in malignant cells. CCR9 protein was localized in
cytoplasm and also on cell membranes, which was clearly
stained with deep yellow or brown-yellow. In addition, nu-
clear CCR9 immunostaining was not observed. High level
of CCR9 expression was detected in 105 (72.9 %) of the
144 lung adenocarcinoma samples, whereas it was de-
tected only in 2 (6.7 %) of the 30 adjacent normal lung tis-
sue samples. Table 1 reveals that the positive expression
rate of CCR9 was significantly greater in the carcinoma
tissue compared with the normal lung parenchymal tissue
(p < 0.001).
CCR9 expression in tumor samples and its correlation
with clinicopathological characteristics
A total of 144 patients with lung adenocarcinoma were
included in our present work. Table 1 summarizes the
relationship between CCR9 protein expression and clini-
copathological characteristics of the patients with lung
adenocarcinoma. According to the classification described
in the section of Methods, immunohistochemical analysis
clearly showed that the CCR9 expression at the protein
level was significantly and positively associated with the
tumor size (P = 0.032). CCR9 was also over-expressed
in patients with lymph node involvement (N1/2 vs. N0;
85.3 % vs. 61.8 %; p = 0.002). High expression of CCR9
was more prevalent in advanced clinical stage cases com-
pared with early clinical stage cases (80.5 % and 61.4 %, re-
spectively; p = 0.012). In addition, the positive expression
rate of CCR9 was the highest in low differentiation sub-
group (78.7 %), followed by moderate differentiation sub-
group (74.2 %) and high differentiation subgroup (61.3 %).
Moreover, a trend was observed between the CCR9 expres-
sion and pathologic differentiation, although it was not
significant (p = 0.225). Statistical analysis revealed that
there was no significant correlation between the CCR9
Fig. 1 Expression of CCR9 in lung adenocarcinoma and normal lung tissues based on immunohistochemistry. a Negative expression in adjacent
normal lung tissue; b Negative expression in lung adenocarcinoma tissue; c Positive expression of CCR9 in lung adenocarcinoma tissue; d Strong
positive expression of CCR9 in lung adenocarcinoma tissue. CCR9, CC chemokine receptor9
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expression and the age, gender, chemotherapy and differen-
tiation status of patients (p > 0.05).
OS and prognostic significance of CCR9 expression in
lung adenocarcinoma
OS analysis using the Kaplan-Meier method showed that
patients with negative CCR9 expression had higher OS
compared with those with positive CCR9 expression
(Fig. 2; log rank value =7.750, P = 0.005). The survival
rate of CCR9 negative patients who received postopera-
tive chemotherapy was higher than those received single
surgery (Fig. 3; log rank value =14.255, P < 0.001). More-
over, upon the univariate analysis using the cox propor-
tional hazards model, positive lymph node metastasis
(HR = 1.71, P = 0.021), advanced TNM stage (HR = 2.184,
P = 0.002), postoperative chemotherapy (HR = 0.628, P =
0.044) and positive CCR9 expression (HR = 2.189, P =
0.007) were associated with increased risk of death in the
patients with lung adenocarcinoma. In the multivariate
analyses, positive CCR9 expression remained predictive
for OS after adjustment of lymph node status, TNM stage
and chemotherapy as covariates (HR = 1.948, P = 0.028;
Table 1 Association of CCR9 expression with clinicopathological characteristics from lung adenocarcinoma
Group Cases Negative expression n (%) Positive expression n (%) p-value
Cancer 144 39 (27.1) 105 (72.9)
Normal lung 30 28 (93.3) 2 (6.7) < 0.001*
Gender
Male 95 24 (25.3) 71 (74.7)
Female 49 15 (30.6) 34 (69.4) 0.494
Ages (years)
≤ 60 88 22 (25.0) 66 (75.0)
> 60 56 17 (30.4) 39 (69.6) 0.481
Differentiation
High 31 12 (38.7) 19 (61.3)
Moderate 66 17 (25.8) 49 (74.2) 0.225
Low 47 10 (21.3) 37 (78.7)
Tumor size (cm)
T1 50 19 (38.0) 31 (62.0)
> T2 94 20 (21.3) 74 (78.7) 0.032*
Lymph node status
Yes 68 10 (14.7) 58 (85.3)
No 76 29 (38.2) 47 (61.8) 0.002*
TNM stage
Stage I 57 22 (38.6) 35 (61.4)
Stage II-III 87 17 (19.5) 70 (80.5) 0.012*
Chemotherapy
Yes 73 23(31.5) 50(68.5)
No 71 16(22.5) 55(77.5) 0.226
Note: CCR9, CC chemokine receptor 9; TNM, tumor node metastasis classification system; n, number of cells; *p < 0.05
Fig. 2 Kaplan-Meier curves of overall survival defined by CCR9
expression (n = 144). Patients with negative CCR9 expression had a
greater OS than patients with positive CCR9 expression (Log rank
test, P = 0.005). CCR9, CC chemokine receptor9
Zhong et al. Diagnostic Pathology  (2015) 10:101 Page 4 of 7
Table 2). Except for TNM stage, CCR9 expression
emerged as an independent prognostic indicator of OS for
patients with lung adenocarcinoma.
Discussion
As members of small-molecule superfamily (8–14 kDa),
chemokines are classified into four subgroups (CXC,
CC, C and CX3C) according to the position of their
NH2-terminal cysteine residues [3]. It has been known
that chemokines and their seven trans-membrane G-
protein coupled receptors play roles in regulating the
movement of lymphocytes, natural killer cells and den-
dritic cells under both physiological and pathological
conditions. Muller et al. proposed that tumor cells ac-
complish the process of invasion and metastasis via the
chemokine-mediated mechanisms, such as leukocyte traf-
ficking regulation [12]. The aberrant expression of chemo-
kine receptors has been associated with disease severity,
increased invasiveness of cancer cells, and even poor prog-
nosis in various types of malignancies [13, 14].
CCR9 is primarily involved in immune system, and it
is present on leukocytes and plays critical roles in T
lymphocyte development and recruitment of immune
cells to the small intestine [15]. Recent data have shown
that CCR9 is functionally and significantly expressed in
various cancers, such as acute lymphocytic leukemia
[16], melanoma [17], prostate cancer [18], pancreatic
cancer [19], breast cancer [20], ovarian cancer [21] and
colon cancer [22]. In cancer biology, activation of CCR9
by CCL25 promotes cancer cell migration, invasion and ex-
pression of matrix metalloproteinases (MMPs), which are
key components of cancer invasion and metastasis [23].
In the present study, we analyzed the expression of
CCR9 at the protein level in lung adenocarcinoma tissues
and adjacent normal lung tissues. Interestingly, CCR9 was
expressed at a significantly greater level in tumor tissue
compared with normal tissue (p < 0.001). This finding was
consistent with our previous experimental result that
CCR9 is up-regulated in NSCLC compared with adjacent
normal lung tissue at the transcriptional level [10]. Previ-
ously, we have also shown that over-expressed CCR9 in-
teracts with CCL25 to promote proliferation and suppress
apoptosis of NSCLC cells in vitro, and knockdown of
CCR9 compromises in vivo tumor growth in a nude mice
model [11]. These observations demonstrated that like
other members of the CC chemokine receptor family [13],
CCR9 may function as an oncogene and play an im-
portant role in the tumorigenesis and development of
lung adenocarcinoma.
Although the prognostic significance of CCR9 expression
has not been previously examined in NSCLC, existing evi-
dence suggested that CCR9-CCL25 axis is associated with
cancer aggressiveness, and it might be used as a potential
prognostic indicator in lung cancer. Clinical and patho-
logical staging of cancer is based on TNM system, which is
used to determine the clinical outcome, including thera-
peutic interventions and prognosis [24]. In principle, larger
Fig. 3 Kaplan-Meier curves of overall survival defined by CCR9
expression in the patients who received postoperative platinum-
based chemotherapy (n = 73). Patients who received postoperative
chemotherapy with negative CCR9 expression had a greater OS than
those with positive CCR9 expression (Log rank test, P < 0.001). CCR9,
CC chemokine receptor9
Table 2 Univariate and multivariate analysis of OS in 144 patients with lung adenocarcinoma
Variable Univariate Multivariate
HR 95 % CI(lower-upper) p-value HR 95 % CI(lower-upper) p-value
Gender 0.737 0.452-1.204 0.223 / / /
Age 0.899 0.564-1.433 0.654 / / /
Differentiation 1.121 0.823-1.527 0.468 / / /
Tumor size 1.401 0.858-2.288 0.178 / / /
Lymph node status 1.710 1.083-2.699 0.021* 0.774 0.387-1.547 0.469
TNM stage 2.184 1.327-3.593 0.002* 2.331 1.117-4.863 0.024*
Chemotherapy 0.628 0.399-0.988 0.044* 0.682 0.431-1.081 0.103
CCR9 expression 2.189 1.237-3.873 0.007* 1.948 1.076-3.526 0.028*
Note: CCR9, CC chemokine receptor 9; TNM, tumor node metastasis classification system; HR, hazard ratio; 95 % CI, means 95 % confidence interval; *p < 0.05
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tumor size (T), positive lymph node metastasis and ad-
vanced tumor stage often suggest stronger metastatic
capability and poorer prognosis [25]. Gupta et al. have
recently reported that CCR9-CCL25 interaction pro-
motes lung cancer progression by facilitating the migra-
tion, invasion and metastasis of lung cancer cells, and it
selectively modulates the expression of key metastatic
factors (MMPs and TIMPs) in lung cancer cells follow-
ing CCL25 treatment [26]. Furthermore, the number of
lung adenocarcinoma cells that migrated and invaded
in response to CCL25 is greater compared with lung
squamous cell carcinoma cells. The expression and ac-
tivity of MMP-2 in response to CCL25 were greater
in lung adenocarcinoma cells compared with squamous cell
carcinoma cells [26]. Interestingly, our current founding
showed that higher expression of CCR9 could be linked
with tumor size in lung adenocarcinoma; the positive ex-
pression rate of CCR9 (58/68, 85.3 %) in tumor tissue with
lymph node metastasis was greater than that without
lymph node metastasis (47/76, 61.8 %). Moreover, higher
expression of CCR9 in lung adenocarcinoma was signifi-
cantly correlated with advanced TNM stage (p = 0.012). In
addition, we observed a clear trend between CCR9 expres-
sion and pathologic differentiation, although this trend
was not significant (p = 0.225). In the previous study, we
have found that CCR9-CCL25 axis plays a significant role
in survival of NSCLC cells by inhibiting cancer cell apop-
tosis both in vitro and in vivio through the activation of
PI3K/Akt signaling pathway, and cell survival is essential
for cancer cells to achieve invasion and metastasis [11].
Therefore, over-expression of CCR9 in lung adenocar-
cinoma suggested its crucial role in disseminating pri-
mary tumor and promoting tumor cell survival during
metastasis. Li et al. reported that high CCR9 expression
is detected in tumor tissue and tumor draining lymph
nodes in patients with pancreatic cancer, which is posi-
tively associated with cancer progression and metastasis
[27]. These results indicated that the CCR9 expression
might be predictive for lymph node metastasis in pa-
tients with lung adenocarcinoma, therefore more ag-
gressive treatment should be considered in the patients
at high risk of lymph node metastasis.
Zhang et al. reported that ectopic expression of CCR9
not only enhances cell proliferation and tumorigenicity
in hepatocellular carcinoma cells, but also acts as a novel
prognostic marker and therapeutic target for hepatocel-
lular carcinoma [9]. Similarly, Li et al. demonstrated that
positive expression of CCR9 is significantly correlated
with poor prognosis in patients with pancreatic cancer
[27]. Nevertheless, it remains elusive whether these find-
ings of CCR9 can be extended to lung adenocarcinoma
patients. In this study, we, for the first time, reported the
prognostic value of CCR9 expression for postopera-
tive patients with lung adenocarcinoma. According to
Kaplan-Meier survival analysis, expression of CCR9 was
negatively associated with OS in lung adenocarcinoma,
as the patients with positive CCR9 expression exhibited
a poorer OS. Johnson et al. demonstrated that ovarian
cancer cells and tissue express CCR9, and the interaction
between CCR9 and CCL25 increases anti-apoptotic sig-
naling cascades in ovarian cells, which rescues cells from
cisplatin-induced death [28]. The similar result has been
observed in breast cancer in vitro that CCR9-CCL25 axis
inhibits cisplatin-induced apoptosis in a PI3K-dependent
and FAK-independent fashion [29]. Although no previ-
ous study has investigated the relationship between
CCR9 and chemotherapy in lung cancer, interestingly,
among the lung adenocarcinoma patients who received
postoperative platinum-based chemotherapy, the pa-
tients with negative CCR9 expression had a significant
better prognosis. It is necessary to further clarify the
underlying molecular mechanism of CCL25-CCR9 axis
on lung adenocarcinoma. Furthermore, after adjustment
of lymph node status, TNM stage and chemotherapy,
multivariate analysis revealed that CCR9 expression
could be used as an independent factor for predicting post-
operation survival in patients with lung adenocarcinoma.
There were limitations of this study. Firstly, the sample
size was still small, and the uneven distribution of each
subgroup, including the TNM staging of these patients,
might have biased this result. Secondly, many factors
may affect the prognosis of the patients with lung
adenocarcinoma after operation, and there was possible
residual confounding in this study.
Taken together, we, for the first time, investigated the
prognostic impact of CCR9 on lung adenocarcinoma.
The expression of CCR9 was significantly increased in
lung adenocarcinoma tissue. Such an increased CCR9
expression was associated with larger tumor size, posi-
tive lymph node metastasis, advanced clinical stage and
poor prognosis among patients with lung adenocarcin-
oma, suggesting that CCR9 might be a novel prognostic
biomarker for lung adenocarcinoma.
Conclusion
These results suggest for the first time that CCR9
expression may be beneficial in predicting lymph node
metastasis and survival of patients with lung adenocarcin-
oma. A future study will investigate whether CCR9 can
act as a new therapeutic target in lung adenocarcinoma.
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